GLP-1 weight loss drugs

A study found that 32% of patients with eating disorders report using weight loss injections at least once. The research highlights concerns about potential misuse of GLP-1 weight loss drugs among individuals with eating disorders.

A study reveals that 32% of patients with eating disorders have used weight loss injections at least once, raising concerns about potential misuse of GLP-1 drugs.

A study found that 32% of patients with eating disorders report having used a weight loss injection at least once, raising concerns about potential misuse of GLP-1 weight loss drugs.

A study found that 32% of patients with eating disorders have used a weight loss injection at least once, raising concerns about potential misuse of GLP-1 weight loss drugs.

Whey protein prices have nearly doubled due to increased demand for high-protein foods, driven by GLP-1 weight loss drugs and revised dietary guidelines. Companies face supply shortages and must choose between absorbing costs or compromising product quality, as switching to alternative proteins proves challenging due to taste and texture issues.

GLP-1 weight loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound are popular, prompting competitors like Pfizer and Amgen to develop similar products. The article discusses market competition and strategies by Novo Nordisk and Eli Lilly to maintain dominance in the weight loss drug sector.

People taking GLP-1 weight-loss drugs like Ozempic, Wegovy, Mounjaro, and Zepbound may experience reduced physical activity despite weight loss, according to Fitbit data analysis. Researchers noted declines in daily steps and exercise levels, raising concerns about muscle mass loss and long-term health impacts.

The article highlights a growing number of overdoses linked to GLP-1 weight loss drugs, as reported in an investigative piece by NBC News in collaboration with KFF Health News.

Body acceptance advocate Katie Sturino, founder of Megababe Beauty, discusses her challenging decision to start GLP-1 weight loss drugs. Psychiatrist Dr. Sue Varma provides guidance on pre-treatment considerations and examines the influence of societal pressure on such decisions.